The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global ablation devices market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 11% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Ablation devices are minimally invasive (MI) medical instruments used for the removal, or excision, or abnormal body tissues for therapeutic purposes. Some of the commonly used ablation devices include temperature-controlled, fluid-cooled, robotic catheter manipulation and laser ablators, tissue contact and spray probes and balloon ablation devices. They operate using radiofrequency (RF), laser, ultrasound, cryoablation, microwave and hydrothermal technologies. They are used as an alternative to surgical treatment for various chronic diseases and the removal of cancerous tumors and kidney stones. Ablation devices are also utilized for the management of chronic lower back, neck and arthritis pain. As a result, they find extensive applications in the treatment of ophthalmological, oncological, gynecological, urological and cardiovascular disorders.
The increasing prevalence of life-threatening diseases, such as cancer, atrial fibrillation and chronic venous insufficiency (CVI), is one of the key factors driving the growth of the market. Moreover, rising awareness among the masses regarding the availability of effective ablation procedures is providing a thrust to the market growth. Minimally invasive ablation procedures cause lesser pain, scarring, discomfort and promote faster recovery in the patients. In line with this, the widespread adoption of electrophysiology to remove abnormal tissues that cause irregular heart rhythms or cardiac arrhythmia is also contributing to the growth of the market. Additionally, various product innovations, such as the development of next-generation ablation devices with robotic navigation systems, are acting as other growth-inducing factors. Product manufacturers are developing non-thermal, non-tumescent and non-sclerosant endovenous ablation devices for the effective treatment of superficial vein reflux. Other factors, including rising healthcare expenditure capacities of the consumers, along with significant improvements in the medical industry, especially in the developing economies, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global ablation devices market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on device technology, application and end user.
Breakup by Device Technology:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AngioDynamics Inc., AtriCure Inc., Boston Scientific Corporation, CONMED Corporation, Elekta AB (publ), Johnson & Johnson, Medtronic plc, Olympus Corporation and Smith & Nephew plc.
|Base Year of the Analysis||2020|
|Segment Coverage||Device Technology, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, AngioDynamics Inc., AtriCure Inc., Boston Scientific Corporation, CONMED Corporation, Elekta AB (publ), Johnson & Johnson, Medtronic plc, Olympus Corporation and Smith & Nephew plc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at